Nephrotic Syndrome Panel

Test code: KI0401

In addition, it also includes the maternally inherited mitochondrial genome. Is ideal for patients with nephrotic syndrome

The panel covers genes associated with autosomal recessive, autosomal dominant and X-linked forms of the disease.

About Nephrotic Syndrome

Nephrotic syndrome is caused by a leaky glomerular filtration barrier resulting in extensive proteinuria, hypoalbuminemia, hyperlipidemia and edema. The majority of patients (80-90%) with nephrotic syndrome are responsive to steroid treatment and achieve remission with a good long-term prognosis. The remaining 10-20% are considered to have steroid-resistant nephrotic syndrome (SRNS). Some of these patients may respond to other immunosuppressive therapies. The prognosis of steroid-resistant nephrotic syndrome is poor, as 30–40% develop end-stage renal disease (ESRD) requiring dialysis and transplantation (PMID: 19280229). Decades of extensive research have revealed important insights into the molecular genetic structure and function of the glomerular filtration barrier. Identification of nephrin gene (NPHS1) mutation, causing congenital nephropathy of Finnish type, opened up a new era in the understanding of the pathophysiology and genetics of proteinuric diseases. Identified genes, their mutations, and genotype-phenotype correlations are now being translated into everyday clinical practice through genetic testing. Ineffective treatment with steroids and other immunosuppressives can be avoided with genetic testing in patients with nephrotic syndrome (PMID: 20798252). Identification of causative mutations can also be used in the prediction of increased risk of post-transplant proteinuria. Post-transplant recurrence is generally high but almost unknown in patients with a genetic origin of the disease. After establishing a genetic diagnosis, transplantation, particularly live related transplantation, may be explored as a therapeutic option in the early phases of the disease (PMID: 20798252). This nephrotic syndrome panel also includes disorders resulting in progressive renal failure such as Alport syndrome.

Availability

Results in 3-4 weeks

Gene set description

Genes in the Nephrotic Syndrome Panel and their clinical significance

<table>
<thead>
<tr>
<th>Gene</th>
<th>Associated phenotypes</th>
<th>Inheritance</th>
<th>ClinVar</th>
<th>HGMD</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACTN4*</td>
<td>Focal segmental glomerulosclerosis</td>
<td>AD</td>
<td>4</td>
<td>31</td>
</tr>
<tr>
<td>ADCK4</td>
<td>Nephrotic syndrome</td>
<td>AR</td>
<td>11</td>
<td>27</td>
</tr>
<tr>
<td>ANLN</td>
<td>Focal segmental glomerulosclerosis</td>
<td>AD</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>APOL1*</td>
<td>Sporadic idiopathic steroid-resistant nephrotic syndrome with focal segmental hyalinosis</td>
<td>AD/AR</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>ARH GAP24</td>
<td>Familial idiopathic steroid-resistant nephrotic syndrome with focal segmental hyalinosis</td>
<td>AD/AR</td>
<td>3</td>
<td>10</td>
</tr>
<tr>
<td>ARHG DIA</td>
<td>Nephrotic syndrome</td>
<td>AR</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>CD2AP</td>
<td>Glomerulosclerosis, focal segment</td>
<td>AR</td>
<td>3</td>
<td>14</td>
</tr>
<tr>
<td>COL4A3</td>
<td>Alport syndrome, Hematuria, benign familial</td>
<td>AD/AR</td>
<td>123</td>
<td>264</td>
</tr>
<tr>
<td>COL4A4</td>
<td>Alport syndrome</td>
<td>AD/AR</td>
<td>110</td>
<td>232</td>
</tr>
<tr>
<td>Gene</td>
<td>Condition</td>
<td>Inheritance</td>
<td>Chromosome</td>
<td>Position</td>
</tr>
<tr>
<td>----------</td>
<td>----------------------------------------------------------------------------</td>
<td>-------------</td>
<td>------------</td>
<td>----------</td>
</tr>
<tr>
<td>COL4A5</td>
<td>Alport syndrome</td>
<td>XL</td>
<td>7</td>
<td>992</td>
</tr>
<tr>
<td>COQ2</td>
<td>Coenzyme Q10 deficiency</td>
<td>AR</td>
<td>16</td>
<td>31</td>
</tr>
<tr>
<td>CRB2</td>
<td>Focal segmental glomerulosclerosis, Ventriculomegaly with cystic kidney disease</td>
<td>AR</td>
<td>12</td>
<td>22</td>
</tr>
<tr>
<td>DGKE</td>
<td>Nephrotic syndrome</td>
<td>AR</td>
<td>17</td>
<td>38</td>
</tr>
<tr>
<td>DLC1</td>
<td>Nephrotic syndrome</td>
<td>AR</td>
<td>5</td>
<td>22</td>
</tr>
<tr>
<td>EMP2</td>
<td>Nephrotic syndrome</td>
<td>AR</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>FAN1</td>
<td>Interstitial nephritis, karyomegalic</td>
<td>AR</td>
<td>12</td>
<td>21</td>
</tr>
<tr>
<td>FAT1</td>
<td>Nephrotic syndrome</td>
<td>AR</td>
<td>2</td>
<td>36</td>
</tr>
<tr>
<td>FN1</td>
<td>Glomerulopathy with fibronectin deposits 2</td>
<td>AD</td>
<td>14</td>
<td>25</td>
</tr>
<tr>
<td>INF2</td>
<td>Glomerulosclerosis, Charcot-Marie-Tooth disease</td>
<td>AD</td>
<td>20</td>
<td>67</td>
</tr>
<tr>
<td>ITGA3</td>
<td>Interstitial lung disease with nephrotic syndrome and epidermolysis bullosa</td>
<td>AR</td>
<td>6</td>
<td>11</td>
</tr>
<tr>
<td>KANK1</td>
<td>Cerebral palsy, spastic quadriplegic, 2, Nephrotic syndrome</td>
<td>AD</td>
<td>4</td>
<td>10</td>
</tr>
<tr>
<td>KANK2</td>
<td>Palmoplantar keratoderma and woolly hair, Nephrotic syndrome</td>
<td>AR</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>KANK4</td>
<td>Nephrotic syndrome</td>
<td>AR</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>LAMB2</td>
<td>Nephrotic syndrome, Pierson syndrome</td>
<td>AR</td>
<td>20</td>
<td>122</td>
</tr>
<tr>
<td>LMX1B</td>
<td>Nail-patella syndrome</td>
<td>AD</td>
<td>26</td>
<td>194</td>
</tr>
<tr>
<td>MAFB</td>
<td>Multicentric carpotarsal osteolysis</td>
<td>AD</td>
<td>13</td>
<td>23</td>
</tr>
<tr>
<td>MAGI2</td>
<td>Nephrotic syndrome 15</td>
<td>AR</td>
<td>7</td>
<td>27</td>
</tr>
<tr>
<td>MT-ATP6</td>
<td>Neuropathy, ataxia, and retinitis pigmentosa, Leber hereditary optic neuropathy, Ataxia and polyneuropathy, adult-onset, Cardiomyopathy, infantile hypertrophic, Leigh syndrome, Striatonigral degeneration, infantile, mitochondrial</td>
<td>Mitochondrial</td>
<td>19</td>
<td></td>
</tr>
<tr>
<td>MT-ATP8</td>
<td>Cardiomyopathy, apical hypertrophic, and neuropathy, Cardiomyopathy, infantile hypertrophic</td>
<td>Mitochondrial</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>MT-CO1</td>
<td>Myoglobinuria, recurrent, Leber hereditary optic neuropathy, Sideroblastic anemia, Cytochrome C oxidase deficiency</td>
<td>Mitochondrial</td>
<td>17</td>
<td></td>
</tr>
<tr>
<td>MT-CO2</td>
<td>Cytochrome c oxidase deficiency</td>
<td>Mitochondrial</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>MT-CO3</td>
<td>Cytochrome c oxidase deficiency, Leber hereditary optic neuropathy</td>
<td>Mitochondrial</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>MT-CYB</td>
<td>Leber hereditary optic neuropathy</td>
<td>Mitochondrial</td>
<td>69</td>
<td></td>
</tr>
<tr>
<td>MT-ND1</td>
<td>Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes, Leber hereditary optic neuropathy, Leber optic atrophy and dystonia</td>
<td>Mitochondrial</td>
<td>21</td>
<td></td>
</tr>
<tr>
<td>MT-ND2</td>
<td>Leber hereditary optic neuropathy, Mitochondrial complex I deficiency</td>
<td>Mitochondrial</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>Gene</td>
<td>Description</td>
<td>Mitochondrial</td>
<td>Chromosome</td>
<td></td>
</tr>
<tr>
<td>--------</td>
<td>------------------------------------------------------------------------------------------------------------</td>
<td>---------------</td>
<td>------------</td>
<td></td>
</tr>
<tr>
<td>MT-ND3</td>
<td>Leber optic atrophy and dystonia, Mitochondrial complex I deficiency</td>
<td>Mitochondrial</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>MT-ND4</td>
<td>Leber hereditary optic neuropathy, Leber optic atrophy and dystonia, Mitochondrial complex I deficiency</td>
<td>Mitochondrial</td>
<td>11</td>
<td></td>
</tr>
<tr>
<td>MT-ND4L</td>
<td>Leber hereditary optic neuropathy</td>
<td>Mitochondrial</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>MT-ND5</td>
<td>Myoclonic epilepsy with ragged red fibers, Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes, Leber hereditary optic neuropathy, Mitochondrial complex I deficiency</td>
<td>Mitochondrial</td>
<td>19</td>
<td></td>
</tr>
<tr>
<td>MT-ND6</td>
<td>Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes, Oncocytoma, Leber hereditary optic neuropathy, Leber optic atrophy and dystonia, Mitochondrial complex I deficiency</td>
<td>Mitochondrial</td>
<td>16</td>
<td></td>
</tr>
<tr>
<td>MT-RNR1</td>
<td>Deafness, mitochondrial</td>
<td>Mitochondrial</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>MT-RNR2</td>
<td>Chloramphenicol toxicity/resistance</td>
<td>Mitochondrial</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>MT-TA</td>
<td>Leber hereditary optic neuropathy, Mitochondrial multisystemic disorder, Progressive external ophthalmoplegia, Dilated cardiomyopathy (DCM)</td>
<td>Mitochondrial</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>MT-TC</td>
<td>Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes</td>
<td>Mitochondrial</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>MT-TD</td>
<td>Mitochondrial multisystemic disorder</td>
<td>Mitochondrial</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>MT-TE</td>
<td>Diabetes-deafness syndrome, Mitochondrial myopathy, infantile, transient, Mitochondrial myopathy with diabetes</td>
<td>Mitochondrial</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>MT-TF</td>
<td>Myoclonic epilepsy with ragged red fibers, Nephropathy, tubulointerstitial, Encephalopathy, mitochondrial, Epilepsy, mitochondrial, Myopathy, mitochondrial, Mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes</td>
<td>Mitochondrial</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>MT-TG</td>
<td>Hypertrophic cardiomyopathy, Encephalopathy, Myopathy</td>
<td>Mitochondrial</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>MT-TH</td>
<td>Mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes</td>
<td>Mitochondrial</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>MT-TI</td>
<td>Progressive external ophthalmoplegia</td>
<td>Mitochondrial</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>MT-TK</td>
<td>Myoclonic epilepsy with ragged red fibers</td>
<td>Mitochondrial</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>MT-TL1</td>
<td>Cytochrome c oxidase deficiency, Myoclonic epilepsy with ragged red fibers, Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes, Diabetes-deafness syndrome, Cyclic vomiting syndrome, SIDS, susceptibility to</td>
<td>Mitochondrial</td>
<td>14</td>
<td></td>
</tr>
<tr>
<td>MT-TL2</td>
<td>Progressive external ophthalmoplegia, Mitochondrial multisystemic disorder</td>
<td>Mitochondrial</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>MT-TM</td>
<td>Mitochondrial Myopathy, Leigh syndrome, Mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes</td>
<td>Mitochondrial</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>MT-TN</td>
<td>Progressive external ophthalmoplegia</td>
<td>Mitochondrial</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>MT-TP</td>
<td>Mitochondrial multisystemic disorder</td>
<td>Mitochondrial</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>MT-TQ</td>
<td>Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes, Encephalopathy</td>
<td>Mitochondrial</td>
<td>2</td>
<td></td>
</tr>
</tbody>
</table>
MT-TR  Dilated cardiomyopathy (DCM)  Mitochondrial  2
MT-TS1  Myoclonic epilepsy with ragged red fibers, Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes  Mitochondrial  10
MT-TS2  Mitochondrial multisystemic disorder  Mitochondrial  2
MT-TT  Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes  Mitochondrial  5
MT-TV  Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes  Mitochondrial  3
MT-TW  Leigh syndrome, Mitochondrial Myopathy  Mitochondrial  8
MT-TY  Mitochondrial multisystemic disorder  Mitochondrial  4
MYH9  Sebastian syndrome, May-Hegglin anomaly, Epstein syndrome, Fechtner syndrome, Macrothrombocytopenia and progressive sensorineural deafness, Deafness, autosomal dominant 17  AD  25  117
MYO1E  Focal segmental glomerulosclerosis  AR  3  22
NPHS1  Nephrotic syndrome  AR  171  318
NPHS2  Nephrotic syndrome  AR  54  208
NUP107  Nephrotic syndrome, type 11  AR  6  12
NUP93  Nephrotic syndrome  AR  5  9
OSGEP  Galloway-Mowat syndrome  AR  11  17
PLCE1  Nephrotic syndrome  AR  13  62
PTPRO  Nephrotic syndrome  AR  3  10
SCARB2  Epilepsy, progressive myoclonic  AR  23  27
SGPL1  Nephrotic syndrome  AR  8  17
SMARCAL1  Schimke immunoosseous dysplasia  AR  20  88
TRPC6  Focal segmental glomerulosclerosis  AD  13  45
TTC21B  Short-rib thoracic dysplasia, Nephronophthisis, Asphyxiating thoracic dysplasia (ATD; Jeune)  AR  23  63
WDR73  Galloway-Mowat syndrome  AR  9  12
WT1  Denys-Drash syndrome, Frasier syndrome, Wilms tumor, Nephrotic syndrome, type 4  AD  42  183
XPO5  Nephrotic syndrome  AR  3

*Some regions of the gene are duplicated in the genome. [Read more.](https://blueprintgenetics.com/)

# The gene has suboptimal coverage (means <90% of the gene’s target nucleotides are covered at >20x with mapping quality score (MQ>20) reads), and/or the gene has exons listed under Test limitations section that are not included in the panel as they are not sufficiently covered with high quality sequence reads.

The sensitivity to detect variants may be limited in genes marked with an asterisk (*) or number sign (#)
Gene refers to the HGNC approved gene symbol; Inheritance refers to inheritance patterns such as autosomal dominant (AD), autosomal recessive (AR), mitochondrial (mi), X-linked (XL), X-linked dominant (XLD) and X-linked recessive (XLR); ClinVar refers to the number of variants in the gene classified as pathogenic or likely pathogenic in this database (ClinVar); HGMD refers to the number of variants with possible disease association in the gene listed in Human Gene Mutation Database (HGMD). The list of associated, gene specific phenotypes are generated from CGD or Mitomap databases.

## Non-coding disease causing variants covered by the panel

<table>
<thead>
<tr>
<th>Gene</th>
<th>Genomic location HG19</th>
<th>HGVS</th>
<th>RefSeq</th>
<th>RS-number</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACTN4</td>
<td>Chr19:39137810</td>
<td>c.-34C&gt;T</td>
<td>NM_004924.4</td>
<td>rs1355503133</td>
</tr>
<tr>
<td>ACTN4</td>
<td>Chr19:39138352</td>
<td>c.2224-11C&gt;T</td>
<td>NM_000091.4</td>
<td></td>
</tr>
<tr>
<td>COL4A3</td>
<td>Chr2:228145145</td>
<td>c.4028-27A&gt;G</td>
<td>NM_000091.4</td>
<td></td>
</tr>
<tr>
<td>COL4A3</td>
<td>Chr2:228168708</td>
<td>c.4462+457C&gt;G</td>
<td>NM_000091.4</td>
<td></td>
</tr>
<tr>
<td>COL4A3</td>
<td>Chr2:228173092</td>
<td>c.4463-18dupA</td>
<td>NM_000091.4</td>
<td>rs769590145</td>
</tr>
<tr>
<td>COL4A4</td>
<td>Chr2:227875240</td>
<td>c.4334-23A&gt;G</td>
<td>NM_000092.4</td>
<td></td>
</tr>
<tr>
<td>COL4A5</td>
<td>ChrX:107813924</td>
<td>c.385-719G&gt;A</td>
<td>NM_033380.2</td>
<td>rs104886396</td>
</tr>
<tr>
<td>COL4A5</td>
<td>ChrX:107816792</td>
<td>c.466-12G&gt;A</td>
<td>NM_033380.2</td>
<td>rs104886414</td>
</tr>
<tr>
<td>COL4A5</td>
<td>ChrX:107820077</td>
<td>c.609+875G&gt;T</td>
<td>NM_033380.2</td>
<td></td>
</tr>
<tr>
<td>COL4A5</td>
<td>ChrX:107821295</td>
<td>c.646-12_646-11delTT</td>
<td>NM_033380.2</td>
<td>rs104886436</td>
</tr>
<tr>
<td>COL4A5</td>
<td>ChrX:107834930</td>
<td>c.1423+57dupC</td>
<td>NM_033380.2</td>
<td>rs104886328</td>
</tr>
<tr>
<td>COL4A5</td>
<td>ChrX:107838719</td>
<td>c.1424-20T&gt;A</td>
<td>NM_033380.2</td>
<td>rs281874668</td>
</tr>
<tr>
<td>COL4A5</td>
<td>ChrX:107842994</td>
<td>c.1948+894C&gt;G</td>
<td>NM_033380.2</td>
<td></td>
</tr>
<tr>
<td>COL4A5</td>
<td>ChrX:107845097</td>
<td>c.2042-18A&gt;G</td>
<td>NM_033380.2</td>
<td>rs104886341</td>
</tr>
<tr>
<td>COL4A5</td>
<td>ChrX:107849932</td>
<td>c.2245-40A&gt;G</td>
<td>NM_033380.2</td>
<td></td>
</tr>
<tr>
<td>COL4A5</td>
<td>ChrX:107849958</td>
<td>c.2245-14T&gt;A</td>
<td>NM_033380.2</td>
<td></td>
</tr>
<tr>
<td>COL4A5</td>
<td>ChrX:107852872</td>
<td>c.2395+2750A&gt;G</td>
<td>NM_033380.2</td>
<td></td>
</tr>
<tr>
<td>COL4A5</td>
<td>ChrX:107908726</td>
<td>c.3374-11C&gt;A</td>
<td>NM_033380.2</td>
<td>rs104886387</td>
</tr>
<tr>
<td>COL4A5</td>
<td>ChrX:107933678</td>
<td>c.4529-2300T&gt;G</td>
<td>NM_033380.2</td>
<td></td>
</tr>
<tr>
<td>COL4A5</td>
<td>ChrX:107935633</td>
<td>c.4529-345A&gt;G</td>
<td>NM_033380.2</td>
<td></td>
</tr>
<tr>
<td>COL4A5</td>
<td>ChrX:107938272</td>
<td>c.4821+121T&gt;C</td>
<td>NM_033380.2</td>
<td>rs104886423</td>
</tr>
<tr>
<td>COL4A5</td>
<td>ChrX:107938337</td>
<td>c.4822-152dupT</td>
<td>NM_033380.2</td>
<td></td>
</tr>
<tr>
<td>COL4A5</td>
<td>ChrX:107938346</td>
<td>c.4822-151_4822-150insT</td>
<td>NM_033380.2</td>
<td>rs397515494</td>
</tr>
</tbody>
</table>
Test Strengths

The strengths of this test include:

- CAP accredited laboratory
- CLIA-certified personnel performing clinical testing in a CLIA-certified laboratory
- Powerful sequencing technologies, advanced target enrichment methods and precision bioinformatics pipelines ensure superior analytical performance
- Careful construction of clinically effective and scientifically justified gene panels
- Some of the panels include the whole mitochondrial genome (please see the Panel Content section)
- Our Nucleus online portal providing transparent and easy access to quality and performance data at the patient level
- Our publicly available analytic validation demonstrating complete details of test performance
- ~2,000 non-coding disease causing variants in our clinical grade NGS assay for panels (please see 'Non-coding disease causing variants covered by this panel' in the Panel Content section)
- Our rigorous variant classification scheme
- Our systematic clinical interpretation workflow using proprietary software enabling accurate and traceable processing of NGS data
- Our comprehensive clinical statements

Test Limitations

Genes with partial, or whole gene, segmental duplications in the human genome are marked with an asterisk (*) if they overlap with the UCSC pseudogene regions. The technology may have limited sensitivity to detect variants in genes marked with these symbols (please see the Panel content table above).

This test does not detect the following:

- Complex inversions
- Gene conversions
- Balanced translocations
- Some of the panels include the whole mitochondrial genome but not all (please see the Panel Content section)
- Repeat expansion disorders unless specifically mentioned
- Non-coding variants deeper than ±20 base pairs from exon-intron boundary unless otherwise indicated (please see above Panel Content / non-coding variants covered by the panel).

This test may not reliably detect the following:

- Low level mosaicism in nuclear genes (variant with a minor allele fraction of 14.6% is detected with 90% probability)
- Stretches of mononucleotide repeats
- Low level heteroplasmy in mtDNA (>90% are detected at 5% level)
Indels larger than 50bp
- Single exon deletions or duplications
- Variants within pseudogene regions/duplicated segments
- Some disease causing variants present in mtDNA are not detectable from blood, thus post-mitotic tissue such as skeletal muscle may be required for establishing molecular diagnosis.

The sensitivity of this test may be reduced if DNA is extracted by a laboratory other than Blueprint Genetics.

For additional information, please refer to the Test performance section and see our Analytic Validation.

**Test performance**

The Blueprint Genetics nephrotic syndrome panel covers classical genes associated with nephrotic syndrome. The genes on the panel have been carefully selected based on scientific literature, mutation databases and our experience.

Our panels are sliced from our high-quality whole exome sequencing data. Please see our sequencing and detection performance table for details regarding our ability to detect different types of alterations (Table).

Assays have been validated for different starting materials including EDTA-blood, isolated DNA (no FFPE), saliva and dry blood spots (filter card) and all provide high-quality results. The diagnostic yield varies substantially depending on the assay used, referring healthcare professional, hospital and country. Blueprint Genetics’ Plus Analysis (Seq+Del/Dup) maximizes the chance to find a molecular genetic diagnosis for your patient although Sequence Analysis or Del/Dup Analysis may be a cost-effective first line test if your patient’s phenotype is suggestive of a specific mutation type.

The genes on the panel have been carefully selected based on scientific literature, mutation databases and our experience.

Our panels are sectioned from our high-quality, clinical grade NGS assay. Please see our sequencing and detection performance table for details regarding our ability to detect different types of alterations (Table).

<table>
<thead>
<tr>
<th>Alteration Type</th>
<th>Sensitivity % (TP/(TP+FN))</th>
<th>Specificity %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Single nucleotide variants</td>
<td>99.89% (99,153/99,266)</td>
<td>&gt;99.9999%</td>
</tr>
<tr>
<td>Insertions, deletions and indels by sequence analysis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-10 bps</td>
<td>96.9% (7,563/7,806)</td>
<td>&gt;99.9999%</td>
</tr>
<tr>
<td>11-50 bps</td>
<td>99.13% (2,524/2,546)</td>
<td>&gt;99.9999%</td>
</tr>
<tr>
<td>Copy number variants (exon level dels/dups)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 exon level deletion (heterozygous)</td>
<td>100% (20/20)</td>
<td>NA</td>
</tr>
<tr>
<td>1 exon level deletion (homozygous)</td>
<td>100% (5/5)</td>
<td>NA</td>
</tr>
<tr>
<td>1 exon level deletion (het or homo)</td>
<td>100% (25/25)</td>
<td>NA</td>
</tr>
<tr>
<td>2-7 exon level deletion (het or homo)</td>
<td>100% (44/44)</td>
<td>NA</td>
</tr>
<tr>
<td>1-9 exon level duplication (het or homo)</td>
<td>75% (6/8)</td>
<td>NA</td>
</tr>
<tr>
<td>Simulated CNV detection</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5 exons level deletion/duplication</td>
<td>98.7%</td>
<td>100.00%</td>
</tr>
<tr>
<td>Microdeletion/-duplication sdrs (large CNVs, n=37))</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Size range (0.1-47 Mb)</td>
<td>100% (37/37)</td>
<td></td>
</tr>
</tbody>
</table>
The performance presented above reached by Blueprint Genetics high-quality, clinical grade NGS sequencing assay with the following coverage metrics:

<table>
<thead>
<tr>
<th>Mean sequencing depth</th>
<th>143X</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nucleotides with &gt;20x sequencing coverage (%)</td>
<td>99.86%</td>
</tr>
</tbody>
</table>

### Performance of Blueprint Genetics Mitochondrial Sequencing Assay.

<table>
<thead>
<tr>
<th></th>
<th>Sensitivity % (TP/(TP+FN))</th>
<th>Specificity</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ANALYTIC VALIDATION (NA samples; n=4)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Single nucleotide variants</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heteroplasmic (45-100%)</td>
<td>100.0% (50/50)</td>
<td>100.0%</td>
</tr>
<tr>
<td>Heteroplasmic (35-45%)</td>
<td>100.0% (87/87)</td>
<td>100.0%</td>
</tr>
<tr>
<td>Heteroplasmic (25-35%)</td>
<td>100.0% (73/73)</td>
<td>100.0%</td>
</tr>
<tr>
<td>Heteroplasmic (15-25%)</td>
<td>100.0% (77/77)</td>
<td>100.0%</td>
</tr>
<tr>
<td>Heteroplasmic (10-15%)</td>
<td>100.0% (74/74)</td>
<td>100.0%</td>
</tr>
<tr>
<td>Heteroplasmic (5-10%)</td>
<td>100.0% (73/73)</td>
<td>100.0%</td>
</tr>
<tr>
<td>Heteroplasmic (&lt;5%)</td>
<td>100.0% (3/3)</td>
<td>100.0%</td>
</tr>
<tr>
<td><strong>CLINICAL VALIDATION (n=76 samples)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>All types</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Single nucleotide variants n=2084 SNVs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heteroplasmic (45-100%)</td>
<td>100.0% (1940/1940)</td>
<td>100.0%</td>
</tr>
<tr>
<td>Heteroplasmic (35-45%)</td>
<td>100.0% (4/4)</td>
<td>100.0%</td>
</tr>
<tr>
<td>Heteroplasmic (25-35%)</td>
<td>100.0% (3/3)</td>
<td>100.0%</td>
</tr>
<tr>
<td>Heteroplasmic (15-25%)</td>
<td>100.0% (3/3)</td>
<td>100.0%</td>
</tr>
<tr>
<td>Heteroplasmic (10-15%)</td>
<td>100.0% (9/9)</td>
<td>100.0%</td>
</tr>
<tr>
<td>Heteroplasmic (5-10%)</td>
<td>92.3% (12/13)</td>
<td>100.0%</td>
</tr>
<tr>
<td>Heteroplasmic (&lt;5%)</td>
<td>88.7% (47/53)</td>
<td>100.0%</td>
</tr>
<tr>
<td><strong>Insertions and deletions by sequence analysis n=42 indels</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heteroplasmic (45-100%) 1-10bp</td>
<td>100.0% (32/32)</td>
<td>100.0%</td>
</tr>
<tr>
<td>Heteroplasmic (5-45%) 1-10bp</td>
<td>100.0% (3/3)</td>
<td>100.0%</td>
</tr>
<tr>
<td>Heteroplasmic (&lt;5%) 1-10bp</td>
<td>100.0% (5/5)</td>
<td>&gt;0.9999</td>
</tr>
</tbody>
</table>
SIMULATION DATA / (mitomap mutations)

Insertions, and deletions 1-24 bps by sequence analysis; n=17

<table>
<thead>
<tr>
<th>Mutation Type</th>
<th>Homoplasmic (100%) 1-24bp</th>
<th>Heteroplasmic (50%)</th>
<th>Heteroplasmic (25%)</th>
<th>Heteroplasmic (20%)</th>
<th>Heteroplasmic (15%)</th>
<th>Heteroplasmic (10%)</th>
<th>Heteroplasmic (5%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>100.0% (17/17)</td>
<td>100.0% (17/17)</td>
<td>100.0% (17/17)</td>
<td>100.0% (17/17)</td>
<td>100.0% (17/17)</td>
<td>94.1% (16/17)</td>
<td>94.1% (16/17)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>99.99%</td>
<td>100.0%</td>
<td>100.0%</td>
<td>100.0%</td>
<td>100.0%</td>
<td>100.0%</td>
</tr>
</tbody>
</table>

Heteroplasmic (15%)

|                 | 99.98% (16/17)            | 100.0%              | 100.0%              |

Copy number variants (separate artificial mutations; n=1500)

<table>
<thead>
<tr>
<th>Mutation Type</th>
<th>Homoplasmic (100%) 500 bp, 1kb, 5 kb</th>
<th>Heteroplasmic (50%) 500 bp, 1kb, 5 kb</th>
<th>Heteroplasmic (30%) 500 bp, 1kb, 5 kb</th>
<th>Heteroplasmic (20%) 500 bp, 1kb, 5 kb</th>
<th>Heteroplasmic (10%) 500 bp, 1kb, 5 kb</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>100.0%</td>
<td>100.0%</td>
<td>100.0%</td>
<td>99.7%</td>
<td>99.0%</td>
</tr>
<tr>
<td></td>
<td>100.0%</td>
<td>100.0%</td>
<td>100.0%</td>
<td>100.0%</td>
<td>100.0%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>99.7%</td>
<td>99.0%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>100.0%</td>
<td>100.0%</td>
</tr>
</tbody>
</table>

The performance presented above reached by following coverage metrics at assay level (n=66)

<table>
<thead>
<tr>
<th>Metric</th>
<th>Mean of medians</th>
<th>Median of medians</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean sequencing depth MQ0 (clinical)</td>
<td>18224X</td>
<td>17366X</td>
</tr>
<tr>
<td>Nucleotides with &gt;1000x MQ0 sequencing coverage (%) (clinical)</td>
<td>100%</td>
<td></td>
</tr>
<tr>
<td>rho zero cell line (=no mtDNA), mean sequencing depth</td>
<td>12X</td>
<td></td>
</tr>
</tbody>
</table>

Bioinformatics

The target region for each gene includes coding exons and ±20 base pairs from the exon-intron boundary. In addition, the panel includes non-coding variants if listed above (Non-coding variants covered by the panel). Some regions of the gene(s) may be removed from the panel if specifically mentioned in the “Test limitations” section above. The sequencing data generated in our laboratory is analyzed with our proprietary data analysis and annotation pipeline, integrating state-of-the-art algorithms and industry-standard software solutions. Incorporation of rigorous quality control steps throughout the workflow of the pipeline ensures the consistency, validity and accuracy of results. Our pipeline is streamlined to maximize sensitivity without sacrificing specificity. We have incorporated a number of reference population databases and mutation databases such as, but not limited, to 1000 Genomes Project, gnomAD, ClinVar and HGMD into our clinical interpretation software to make the process effective and efficient. For missense variants, in silico variant prediction tools such as SIFT, PolyPhen, MutationTaster are used to assist with variant classification. Through our online ordering and statement reporting system, Nucleus, the customer has an access to details of the analysis, including patient specific sequencing metrics, a gene level coverage plot and a list of regions with inadequate coverage if present. This reflects our mission to build fully transparent diagnostics where customers have easy access to crucial details of the analysis process.
Clinical interpretation

We provide customers with the most comprehensive clinical report available on the market. Clinical interpretation requires a fundamental understanding of clinical genetics and genetic principles. At Blueprint Genetics, our PhD molecular geneticists, medical geneticists and clinical consultants prepare the clinical statement together by evaluating the identified variants in the context of the phenotypic information provided in the requisition form. Our goal is to provide clinically meaningful statements that are understandable for all medical professionals regardless of whether they have formal training in genetics.

Variant classification is the corner stone of clinical interpretation and resulting patient management decisions. Our classifications follow the Blueprint Genetics Variant Classification Schemes based on the ACMG guideline 2015. Minor modifications were made to increase reproducibility of the variant classification and improve the clinical validity of the report. Our experience with tens of thousands of clinical cases analyzed at our laboratory allowed us to further develop the industry standard.

The final step in the analysis of sequence variants is confirmation of variants classified as pathogenic or likely pathogenic using bi-directional Sanger sequencing. Variant(s) fulfilling the following criteria are not Sanger confirmed: the variant quality score is above the internal threshold for a true positive call, and visual check-up of the variant at IGV is in-line with the variant call. Reported variants of uncertain significance are confirmed with bi-directional Sanger sequencing only if the quality score is below our internally defined quality score for true positive call. Reported copy number variations with a size <10 exons are confirmed by orthogonal methods such as qPCR if the specific CNV has been seen less than three times at Blueprint Genetics.

Our clinical statement includes tables for sequencing and copy number variants that include basic variant information (genomic coordinates, HGVS nomenclature, zygosity, allele frequencies, in silico predictions, OMIM phenotypes and classification of the variant). In addition, the statement includes detailed descriptions of the variant, gene and phenotype(s) including the role of the specific gene in human disease, the mutation profile, information about the gene’s variation in population cohorts and detailed information about related phenotypes. We also provide links to the references used, congress abstracts and mutation variant databases used to help our customers further evaluate the reported findings if desired. The conclusion summarizes all of the existing information and provides our rationale for the classification of the variant.

Identification of pathogenic or likely pathogenic variants in dominant disorders or their combinations in different alleles in recessive disorders are considered molecular confirmation of the clinical diagnosis. In these cases, family member testing can be used for risk stratification within the family. In the case of variants of uncertain significance (VUS), we do not recommend family member risk stratification based on the VUS result. Furthermore, in the case of VUS, we do not recommend the use of genetic information in patient management or genetic counseling.

Our interpretation team analyzes millions of variants from thousands of individuals with rare diseases. Thus, our database, and our understanding of variants and related phenotypes, is growing by leaps and bounds. Our laboratory is therefore well positioned to re-classify previously reported variants as new information becomes available. If a variant previously reported by Blueprint Genetics is re-classified, our laboratory will issue a follow-up statement to the original ordering health care provider at no additional cost.

ICD codes

Commonly used ICD-10 codes when ordering the Nephrotic Syndrome Panel

<table>
<thead>
<tr>
<th>ICD-10</th>
<th>Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>F84.2</td>
<td>Rett syndrome</td>
</tr>
<tr>
<td>N04.9</td>
<td>Nephrotic syndrome</td>
</tr>
<tr>
<td>H49.40</td>
<td>Progressive external ophthalmoplegia</td>
</tr>
<tr>
<td>G11.9</td>
<td>Hereditary ataxia</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>--------</td>
<td>------------------------------------------------</td>
</tr>
<tr>
<td>C94.2</td>
<td>Acute Megakaryoblastic Leukemia</td>
</tr>
<tr>
<td>K59.8</td>
<td>Chronic Intestinal Pseudoobstruction</td>
</tr>
<tr>
<td>T36.5</td>
<td>Adverse effect of aminoglycosides</td>
</tr>
<tr>
<td>G93.41</td>
<td>Metabolic Encephalopathy</td>
</tr>
<tr>
<td>H49.81</td>
<td>Kearns Sayre Syndrome</td>
</tr>
<tr>
<td>E88.42</td>
<td>MERFF Syndrome</td>
</tr>
<tr>
<td>H47.013</td>
<td>Nonarteritic Anterior Ischemic Optic Neuropathy</td>
</tr>
<tr>
<td>G60.2</td>
<td>Neuropathy in association with hereditary ataxia</td>
</tr>
<tr>
<td>G30</td>
<td>Alzheimer's Disease</td>
</tr>
<tr>
<td>G25.5</td>
<td>Chorea</td>
</tr>
<tr>
<td>G40</td>
<td>Epilepsy and recurrent seizures</td>
</tr>
<tr>
<td>I42</td>
<td>Cardiomyopathy</td>
</tr>
<tr>
<td>N26.9</td>
<td>Focal Segmental Glomerulosclerosis</td>
</tr>
<tr>
<td>G31.82</td>
<td>Leigh's Disease</td>
</tr>
<tr>
<td>H47.2</td>
<td>Leber's hereditary optic neuropathy</td>
</tr>
<tr>
<td>G71.3</td>
<td>Mitochondrial Myopathy</td>
</tr>
<tr>
<td>I42.1</td>
<td>Hypertrophic Cardiomyopathy</td>
</tr>
<tr>
<td>E11.9</td>
<td>Non-Insulin Dependent Diabetes Mellitus</td>
</tr>
<tr>
<td>Z86.74</td>
<td>Personal history of sudden cardiac arrest</td>
</tr>
<tr>
<td>H90.3</td>
<td>Sensorineural Hearing Loss</td>
</tr>
</tbody>
</table>

**Accepted sample types**

- EDTA blood, min. 1 ml
- Purified DNA, min. 3μg*
- Saliva (Oragene DNA OG-500 kit)

Label the sample tube with your patient’s name, date of birth and the date of sample collection.

Note that we do not accept DNA samples isolated from formalin-fixed paraffin-embedded (FFPE) tissue.

**Resources**

- GeneReviews - Alport Syndrome
- NORD - Alport Syndrome

https://blueprintgenetics.com/
- NephCure
- Nephrotic Syndrome Trust